Amarin and Forest Laboratories Under Review: Drug Makers Face Growing Generic Competition

LONDON, February 15, 2013 /PRNewswire/ –

Last year saw the expiration of patents for several blockbuster drugs,leading to
increasing generic competition. The trend is expected to continue in 2013,with patents on
a number of blockbuster drugs set to expire. For drug manufacturers,intensifying generic
competition is a major concern. Meanwhile,companies such as Amarin Corporation Plc (ADR)
(NASDAQ: AMRN) and Forest Laboratories Inc. (NYSE: FRX) are also assessing the impact of
President Obama’s Affordable Care Act (ACA). StockCall has released free charting and
technical research on these two aforementioned companies. Register to read these reports
at

http://www.stockcall.com/report

Generic Competition

Generic competition is a major concern for major pharmaceutical companies as well as
biotechnology firms. Earlier this month, Merck & Co. had reported a 7% drop in its fourth
quarter profit due to hits from generic competition.

With several blockbuster drugs set to see their patents expire this year, the
competition from generic drugs is expected to intensify. Generic competition is expected
to erode billions of dollars from major pharmaceutical and biotechnology companies’ annual
sales. The key for big pharmaceutical companies, as well as for companies such as Amarin
Corporation Plc and Forest Laboratories Inc., will be to make investments in new drug
discovery and development and create a strong pipeline of products.

Impact of Affordable Care Act (ACA)

Another major development in the pharmaceutical industry has been the Affordable Care
Act (ACA). The U.S. Supreme Court last year upheld the ACA and the healthcare industry is
now preparing for sweeping changes that will hit the industry.

While the ACA has its critics, the reform could ultimately benefit drug manufacturers
as the increase in the number of insured individuals will boost sales. In the near-term
though, the reform may lead to higher costs for companies.

Amarin Corporation Plc Issued Notice of Allowance by USPTO

Earlier this week, Amarin Corporation Plc, which focuses on the commercialization and
development of therapeutics to improve cardiovascular health, said that the United States
Patent and Trademark Office (USPTO) published notification of Notice of Allowance for U.S.
Patent Application Serial Number 13/614,129. The patent is related to Vascepa(R), which is
the company’s first FDA approved product. Sign up for the free report on Amarin
Corporation plc at

http://www.StockCall.com/AMRN021513.pdf

Last month, Amarin Corporation Plc announced that Vascepa capsules, a therapy for
patients in the U.S. to treat severe hypertriglyceridemia, is available by way of
physician prescription.

Joseph Zakrzewski, Chairman and CEO of Amarin Corporation Plc, said that the company
has worked closely with leading clinical experts and regulatory authorities to bring the
important new prescription pure-EPA omega-3 therapy to patients with very high
triglycerides.

Forest Laboratories Inc.’s Q3 Results

Last month, Forest Laboratories Inc. reported its financial results for the third
quarter of fiscal 2013. The company’s GAAP loss per share for the quarter was $0.58. Net
sales for the quarter were $678 million. Forest Laboratories Inc. free technical report
can be accessed by signing up at

http://www.StockCall.com/FRX021513.pdf

Howard Solomon, Chairman and CEO of Forest Laboratories Inc., last month, said that in
the third quarter of fiscal 2013, as expected, the company incurred a loss resulting
principally from sales lost following the expiration of Lexapro’s patent exclusivity in
March 2012. Solomon, however, noted that the company launched two new products in December
2012 and believes that the sales of these products, and the seven products already
launched, will ultimately equal and exceed the sales lost following the expiration of
Lexapro’s exclusivity.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com